Multifunctional NIR bodipy-based photocage, preparation method therefor and use method thereof

By developing a multifunctional NIR BODIPY-based photocage, which utilizes near-infrared light to activate and generate ROS and release drugs, the problem of low drug release efficiency and poor therapeutic effect in existing photoactivated prodrug strategies has been solved, achieving efficient drug release and enhanced therapeutic effect in tumor treatment.

WO2026233423A1PCT designated stage Publication Date: 2026-11-12THE UNIVERSITY OF HONG KONG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/095555
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing photoactivated prodrug strategies for tumor treatment suffer from low drug release efficiency and poor therapeutic effects, especially due to low tissue penetration and high tissue damage. Furthermore, hypoxic tumor regions are inert to photodynamic therapy (PDT), which limits the therapeutic effect.

Method used

We developed a multifunctional near-infrared (NIR) BODIPY-based photocage. By irradiating the photocage with near-infrared light, we triggered the photocage prodrug compound to generate reactive oxygen species (ROS) and release the loaded material. This material then combines with chemotherapeutic agents to form tumor-targeting nanoprodrugs, achieving photoactivated combination therapy (PCT) and enhancing the therapeutic effect.

Benefits of technology

Achieving efficient drug release and cytoplasmic diffusion in the tumor microenvironment enhances anti-tumor immune responses, reduces off-target toxicity, provides precise photoactivated pyroptosis therapy, and improves treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2026095555_12112026_PF_FP_ABST
    Figure CN2026095555_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides a multifunctional NIR BODIPY-based photocage, a preparation method therefor and a use method thereof. The photocage compound has a structure of formula I, and exhibits type I / type II PDT activity and load release ability under NIR light. The present invention provides a new method for combined treatment based on photoactivatable prodrugs and for simplified nanomedicine design.
Need to check novelty before this filing date? Find Prior Art

Description

A multifunctional NIR BODIPY-based photocage and its preparation and application method Technical Field

[0001] This invention relates to the field of pharmaceutical technology, and in particular to a multifunctional NIR BODIPY-based photocage and its preparation and use methods. Background Technology

[0002] Phototherapy is defined as a treatment controlled by light irradiation, enabling precise, on-demand treatment with limited side effects. One common strategy is photodynamic therapy (PDT), which is based on photosensitive molecules that convert oxygen into toxic reactive oxygen species (ROS) to kill tumor cells (A. Grzybowski, J. Sak, J. Pawlikowski, A brief report on the history of phototherapy. Clin Dermatol 34, 532-537 (2016)). PDT has been approved and widely used in clinical practice due to its spatiotemporal controllability and superior therapeutic effects (G. Gunaydin, MEGedik, S. Ayan, Photodynamic Therapy for the Treatment and Diagnosis of Cancer - A Review of the Current Clinical Status. Front Chem 9, 686303 (2021)). However, the efficacy of PDT is highly dependent on the presence of oxygen, and hypoxic regions within tumors are PDT inert (J. F. L. Ovell, T. W. Liu, J. Chen, G. Zheng, Activatable photosensitizers for imaging and therapy. Chem Rev 110, 2839-2857 (2010)). Furthermore, some cases have revealed tumor recurrence after treatment, which may be attributed to various defense mechanisms such as drug efflux, the glutamate system, and DNA repair processes (A. Zamarron et al., Isolation and characterization of PDT-resistant cancer cells. Photochem Photobiol Sci 14, 1378-1389 (2015)).

[0003] Photoactivated prodrug strategies have become a highly promising solution (M. Karimi et al., Smart Nanostructures for Cargo Delivery: Uncaging and Activating by Light. J Am Chem Soc 139, 4584-4610 (2017)). These prodrugs utilize photoprotective groups (PPG, also known as photocages) to conjugate with specific therapeutic molecules (N.-C.Fan, F.-Y.Cheng, J.-AAHo, C.-S.Yeh, Photocontrolled Targeted Drug Delivery: Photocaged Biologically Active Folic Acid as a Light-Responsive Tumor-Targeting Molecule. Angew. Chem. 51, 8806-8810 (2012)). By using light to trigger the breaking of bonds between the photocage and the drug molecule, the controlled delivery of the therapeutic molecule within the biological system is achieved, resulting in light-triggered drug release (Y. Xue et al., Stimulus-cleavable chemistry in the field of controlled drug delivery. Chem Soc Rev 50, 4872-4931 (2021)). Compared to PDT, photocage photoactivation is not dependent on oxygen and provides flexibility in pharmacological action by replacing drug molecules (X. Shan et al., Emerging prodrug-engineered nanomedicines for synergistic chemo-phototherapy. Chem. Eng. J. (Amsterdam, Neth.) 442, 136383 (2022)).Currently, many different photocages have been studied, including 2-nitrophenylmethyl groups (MERoth-Konforti et al., UV Light-Responsive Peptide-Based Supramolecular Hydrogel for Controlled Drug Delivery. Macromol. Rapid Commun. 39, e1800588 (2018)), coumarin-4-ylmethyl groups (K. Long et al., Green light-triggered intraocular drug release for intravenous chemotherapy of retinoblastoma. Advanced Science 8, 2101754 (2021)), and mesomethylboron-dipyrrolemethylene (BODIPY) derivatives (W. Lv, W. Wang, One-Photon Upconversion-Like Photolysis: A New Strategy to Achieve Long-Wavelength Light-Excitable Photolysis. Synlett). 31, 1129-1134 (2020)), and ruthenium (Ru) complexes (J. Liu, W. Kang, W. Wang, Photocleavage-based Photoresponsive Drug Delivery. Photochem Photobiol 98, 288-302 (2022)). However, most of them use short-wavelength light (<650 nm), which presents problems due to low tissue penetration and high tissue damage (X. Zeng, X. Zhou, S. Wu, Red and Near-Infrared Light-Cleavable Polymers. Macromol Rapid Commun 39, e1800034 (2018)). Furthermore, the efficacy of photoactivated prodrugs largely depends on the potency of the drug loading and the release efficiency.

[0004] Therefore, there is still a need to develop light cages with high drug release efficiency and enhanced therapeutic effects (e.g., combined therapy effects) to address the aforementioned shortcomings. Summary of the Invention

[0005] The present invention aims to at least solve one of the aforementioned technical problems existing in the prior art. Therefore, the object of the present invention is to provide an optical cage that solves the aforementioned problems.

[0006] Another object of the present invention is to provide a pharmaceutical composition comprising such a photocage.

[0007] Another object of the present invention is to provide a method for treating a subject’s disease using such a pharmaceutical composition.

[0008] This invention provides a multifunctional near-infrared (NIR) BODIPY-based photocage, as well as its preparation and application methods. This BODIPY-based photocage can be used for photoactivated combination therapy (PCT).

[0009] In some embodiments, the photocage compound includes a reactive functional (i.e., cleavable) group suitable for binding a support (i.e., a drug) and has the structure shown in Formula I:

[0010] Wherein, X is selected from hydrogen or halogen (e.g., iodine, bromine, chlorine) and at least one X group is not hydrogen;

[0011] R1-R5 are each independently selected from hydrogen, C1-C6. 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and at least one of the R1-R5 substituents is not hydrogen;

[0012] R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and R6-R 10 At least one of the substituents is not hydrogen;

[0013] R 11 R 13 Each is independently selected from C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0014] R 12 The R” is a cleavable group selected from –OH, –SH, –NH2, or –NHR”; wherein R” is C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0015] R 14 R 15 Each is independently selected from halogens (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 );and

[0016] R 16 R 17Each is independently selected from hydrogen, C1-C 10 Alkyl groups (e.g., methyl, ethyl).

[0017] A BODIPY light cage, such as the light cage of formula (I), is suitable for attaching a load, such as a drug, thereon.

[0018] In some embodiments, the photocage prodrug compound may have the structure of formula (II):

[0019] Wherein, D is a cleavable drug structural unit containing a photocleavable linker;

[0020] Each X is independently selected from halogens (e.g., iodine, bromine, chlorine);

[0021] R1-R5 are each independently selected from hydrogen, C1-C6. 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and at least one of the R1-R5 substituents is not hydrogen;

[0022] R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and R6-R 10 At least one of the substituents is not hydrogen;

[0023] R 11 R 13 Each is independently selected from C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0024] R 14 R 15 Each is independently selected from halogens (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 );and

[0025] R 16 R 17 Each is independently selected from hydrogen, C1-C 10 Alkyl groups (e.g., methyl, ethyl).

[0026] In some embodiments, the photocage prodrug compound may have the structure of formula II':

[0027] Where L is –O–, –S– or –NH–;

[0028] D represents a cleavable drug structural unit containing a photocleavable linker;

[0029] Each X is independently selected from halogens (e.g., iodine, bromine, chlorine);

[0030] R1-R5 are each independently selected from hydrogen, C1-C6. 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and at least one of the R1-R5 substituents is not hydrogen;

[0031] R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and R6-R 10 At least one of the substituents is not hydrogen;

[0032] R 11 R 13 Each is independently selected from C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0033] R 14 R 15 Each is independently selected from halogens (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 );and

[0034] R 16 R 17 Each is independently selected from hydrogen, C1-C 10 Alkyl groups (e.g., methyl, ethyl).

[0035] The multifunctional BODIPY photocages described herein, such as those of formulas (I)-(II), can be formed as part of a pharmaceutical composition. The pharmaceutical composition comprises an effective amount of the multifunctional BODIPY photocage and optionally one or more pharmaceutically acceptable carriers and / or excipients.

[0036] The multifunctional BODIPY photocages described herein can be used in a variety of medical applications. For example, they can be used for photoactivated combination therapy (PCT) by triggering the release of various therapeutic agents (e.g., reactive oxygen species and drugs) through near-infrared light irradiation. Examples demonstrate the photoactivated anticancer efficacy of various BODIPY photocage prodrugs and nanocarriers against various types of tumors.

[0037] In some implementations, the method of using the multifunctional BODIPY light cage for photoactivated combination therapy (PCT) includes the following steps:

[0038] (i) administering a pharmaceutical composition comprising the multifunctional BODIPY photocage described herein to a subject in need; and

[0039] (ii) Irradiating the photocage prodrug compound of the pharmaceutical composition with sufficient light (e.g., near-infrared light) generates reactive oxygen species (ROS) and induces photolysis and release of at least some cleavable drug structural units.

[0040] The multifunctional BODIPY photocage or the pharmaceutical composition of the multifunctional BODIPY photocage described herein is used in the preparation of drugs for treating tumors.

[0041] In some implementations, the treatment includes photoactivated combination therapy (PCT).

[0042] In some embodiments, the photoactivation combination therapy includes irradiation with light (e.g., infrared light only). Beneficial effects:

[0043] The photocage prodrug compound of the present invention can generate singlet oxygen, superoxide anion and hydroxyl radical, while releasing the loaded material.

[0044] The photocage prodrug compound of this invention can be co-assembled with a controllable chemotherapeutic agent such as IR820-CA4 to form a tumor-targeting nanoprodrug. Under NIR light irradiation, the nanoprodrug generates ROS and releases the chemotherapeutic agent CA4, which activates caspase-3 to cleave RG108-upregulated gasdermin E (GSDME), thereby inducing strong pyroptosis. At the nanoscale, the nanoprodrug completely dissociates after short-term irradiation, promoting efficient drug release and cytoplasmic diffusion. This nanoprodrug represents a precise and controllable platform for pyroptosis-mediated tumor therapy, effectively enhancing the anti-tumor immune response within the tumor microenvironment. In unirradiated areas, the drug molecules remain covalently linked to the photocage, maintaining the stability of the nanoprodrug and minimizing off-target toxicity. Furthermore, the use of optical fiber as a light guide allows for local irradiation at the in situ EC site, providing a practical example for the clinical translation of precise photoactivated pyroptosis therapy. Attached Figure Description

[0045] Figure 1 shows the UV-Vis spectrum of BODIPY photocage 2-5.

[0046] Figure 2 shows the results detected by DPBF measurement. 1 The graph generated by O2 shows the relationship between the A / A0 value at 420 nm and the irradiation time for blank, BODIPY photocage 2-5 and methylene blue (MB).

[0047] Figure 3 shows the O2 detected by DHR123. ·- The generated graph shows the I / I0-1 value at 520 nm (excitation at 505 nm) versus the irradiation time of blank and BODIPY photocages 2-5.

[0048] Figure 4 shows the OH· formation detected by HPF measurement, illustrating the relationship between the I / I0-1 values ​​at 514 nm (excited at 480 nm) and irradiation time for the blank and BODIPY photocage 2-5.

[0049] Figure 5 shows the fluorescence emission pattern of BODIPY photocage 2-5 (excited at 620 nm).

[0050] Figure 6 shows a bar chart summary of the PDT effects of different BODIPY light cages 2-5 and blanks based on ROS detection results for type I and type II.

[0051] Figure 7 shows the DFT calculation results of NIBO's HOMO (left) and LUMO (right) optimized electron densities.

[0052] Figure 8 shows a bar chart of ROS generation for the blank, BODIPY photocage 2-5, and NIBO-RG108 prodrug (denoted as NIRG).

[0053] Figure 9 shows the results obtained by HPLC (656 nm, 100 mW / cm²). 2 The change in light-activated RG108 release over time was measured (0-15 minutes).

[0054] Figure 10 shows the results obtained by HPLC (656 nm, 100 mW / cm). 2 The change in light-activated RG108 release over time was measured (0-15 minutes).

[0055] Figure 11 illustrates the PCT effect of applying NIBO-RG108 prodrug (NIRG prodrug) by near-infrared light irradiation.

[0056] Figure 12 shows a bar chart illustrating the in vitro anticancer efficacy of NIBO, RG108, and NIBO+RG108 on KYSE450 cells under light irradiation.

[0057] Figure 13 shows Western blots of caspase-3 and GSDME in KYSE450 cells under different treatments: blank, RG108, NIRG+hν, and NIBO+hν.

[0058] Figure 14 shows photographs of KYSE450 cells after different treatments, which show different cell death pathways (NIBO + light, cell shrinkage, apoptosis; NIRG + light, cell explosion, pyroptosis).

[0059] Figure 15 shows the HPLC elution curves of free JQ and NIJQ with and without light irradiation.

[0060] Figure 16 shows the UV-Vis spectra of free JQ, NIBO, and NIJQ.

[0061] Figure 17 shows the HPLC elution curves of free Cb and NICb with and without light irradiation.

[0062] Figure 18 shows the UV-Vis spectra of free Cb, NIBO, and NICb.

[0063] Figure 19 illustrates the scheme for the self-assembly of NIRG and IR820-CA4 (820CA) to form nanoprodrugs.

[0064] Figure 20 shows the size and PDI of nanoprodrugs with different ratios of integrated NIRG and 820CA.

[0065] Figure 21 shows the stability of the optimal formulation of NIRG and IR820-CA4 (820CA).

[0066] Figure 22 shows the UV-Vis spectra of NIRG and 820CA and their self-assembled nanoprodrugs.

[0067] Figure 23 shows the SEM images of the NP sample before and after near-infrared light irradiation.

[0068] Figure 24 shows the size changes of the NP sample before and after near-infrared light irradiation.

[0069] Figure 25 shows the near-infrared light illumination (660 nm, 100 mW / cm²). 2 HPLC chromatograms of RG and CA released after the nano-prodrug release.

[0070] Figure 26 shows the near-infrared light illumination (660 nm, 100 mW / cm²). 2 Quantitative detection results of RG and CA released after nano-prodrug release.

[0071] Figure 27 shows ROS generation and live / dead cell staining under different treatments; DCFH-DA was used as the total ROS probe; SOSG was... 1 O2 probe; DHE is O2 ·- The probe, HPF, is an OH· probe. Calcein AM / PI assay is used for live / dead cell staining.

[0072] Figure 28 shows the MTT assay of NPD cytotoxicity in KYSE450 cells with / without light irradiation.

[0073] Figure 29 shows the MTT assay of NPD cytotoxicity in mEC25 cells with / without light irradiation.

[0074] Figure 30 shows the cell morphology after different treatments; the red arrows highlight cell swelling as a marker of pyroptosis.

[0075] Figure 31 shows the Caspase-3 levels after different treatments.

[0076] Figure 32 shows immunofluorescence imaging of intracellular DAMP after different treatments.

[0077] Figure 33 shows ATP levels and LDH release.

[0078] Figure 34 shows the protein blots of GSDME and GSDME-N.

[0079] Figure 35 illustrates the assessment protocol for immunogenic cell death in BMDCs.

[0080] Figure 36 shows CD11c + CD80 in BMDC + (%) (left image) and CD86 + (Right image) proportions.

[0081] Figure 37 illustrates an NPD-based photoactivation therapy regimen in mEC25 tumor mice.

[0082] Figure 38 shows the changes in tumor volume (left) and body weight (right) during the 13-day treatment period (normalized to the initial volume on day 0) (n=4).

[0083] Figure 39 shows the tumor weight during the 13-day treatment period (right panel) (normalized to the initial volume on day 0) and representative images of the tumor collected at the end point (n=4).

[0084] Figure 40 shows the serum IFN-γ and TNF-α levels in different groups at the treatment endpoint (n=3).

[0085] Figure 41 shows CD11c in the spleen. + DC CD80 + CD86 + The gate size and percentage of mature DC cells (n=4).

[0086] Figure 42 shows CD3 in the spleen. + CD8 in T cell population +The sphere and percentage of cytotoxic T cells (n=4).

[0087] Figure 43 shows CD11c in tdLN. + DC CD80 + CD86 + The gate size and percentage of mature DC cells (n=4).

[0088] Figure 44 shows CD3 in tdLN. + CD8 in T cell population + The sphere and percentage of cytotoxic T cells (n=4).

[0089] Figure 45A shows a representative photograph of the assembly structure of a plastic gavage needle and a sheath-type optical fiber; near-infrared light can be transmitted through the optical fiber and emitted from the end of the optical fiber; Figure 45B shows a representative image of near-infrared light therapy on orthotopic EC mice.

[0090] Figure 46 shows representative IVIS photographs of mice on days 0, 3, 9, and 15 during treatment (n=3).

[0091] Figure 47 shows a representative photograph of the esophagus at the end of the study.

[0092] Figure 48 shows the quantification of tumor growth during treatment using luciferase assay (n=3).

[0093] Figure 49 shows the changes in body weight after different treatments.

[0094] Figure 50 shows H&E staining, CD31 and TUNEL immunofluorescence staining of tumors after different treatments.

[0095] Figure 51 shows the NMR spectrum of IR820-CA4.

[0096] Figure 52 shows the inhibitory effect of different groups on tubulin.

[0097] Figure 53 shows the effects of different groups on the cell cycle.

[0098] Figure 54 shows the tumor accumulation of free prodrug and nanoprodrug after intravenous injection in mice with subcutaneous tumors.

[0099] Figure 55 shows the construction process and results of the mouse orthotopic esophageal squamous cell carcinoma model.

[0100] Figure 56 shows the effects of different treatment groups on major organs. Detailed Implementation

[0101] The present invention will be further described in detail below through specific embodiments. Unless otherwise specified, the raw materials, reagents, or apparatus used in the embodiments and comparative examples are all available from conventional commercial sources or can be obtained by existing technical methods. Unless otherwise specified, the test or experimental methods are conventional methods in the art.

[0102] This article describes a multifunctional light cage based on near-infrared (NIR) BODIPY, as well as its manufacturing and application methods. Such BODIPY-based light cages can be used in photoactivated combination therapy (PCT) as described below.

[0103] I. Definition

[0104] It should be understood that, unless otherwise stated, the disclosed compounds, compositions, and methods of use are not limited to specific synthetic methods, specific analytical techniques, or specific reagents, and therefore can vary. It should also be understood that the terminology used herein is for the purpose of describing particular forms and examples only and is not intended to be limiting.

[0105] The term “subject” as used in this article refers to mammals, such as humans.

[0106] The term "effective dose" or "therapeutic effective dose" refers to the dosage of a compound or formulation that is effective in treating, reversing, preventing the progression of, or inhibiting the development of symptoms of one or more diseases or conditions in a subject; for example, it may be used in comparison to a control subject who has not received the compound. The actual effective dose of a compound can vary depending on the specific compound or combination thereof used, the specific pharmaceutical composition formulated, the route of administration, and the subject's age, weight, physical condition, and the severity of the symptoms or conditions to be treated.

[0107] The term "pharmaceutically acceptable" refers to a composition or other material and / or dosage form that, to a reasonable extent of medical judgment, is suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, and is proportionate to a reasonable benefit / risk ratio. The phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or medium, such as a liquid or solid filler, diluent, solvent, or encapsulating material involved in carrying or transporting any subject composition from one organ or part of the body to another. Each carrier must be "acceptable," meaning it is compatible with the other components of the subject composition and will not harm the subject receiving the medication.

[0108] In the context of inhibition, the terms “inhibition” or “reduction” refer to a weakening or reduction in activity and quantity. This can be complete inhibition or reduction of activity or quantity, or partial inhibition or reduction. Inhibition or reduction can be compared to a control or standard level. Inhibition can be measured in percentage values, for example, from 1% to 100%, such as 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, 95%, 99%, or 100%. For example, a pharmaceutical composition comprising one or more types of active pharmaceutical ingredients can reduce the activity and / or quantity of one or more markers of a disease or condition (e.g., cancer) in a subject by about 10%, 20%, 30%, 40%, 50%, 75%, 85%, 90%, 95%, or 99% compared to a subject who has not received or been treated with the composition.

[0109] In the context of disease or symptom, the term "treatment" refers to improving, alleviating, or otherwise preventing the occurrence and progression of a disease, symptom, and / or symptom in animals susceptible to such disease, symptom, and / or symptom but not yet diagnosed with the disease; inhibiting the disease, symptom, or symptom (e.g., hindering its development); and alleviating the disease, symptom, or symptom (e.g., promoting the resolution of the disease, symptom, and / or symptom). Treatment of a disease or symptom includes improving at least one symptom of a specific disease or symptom, even without intervening in the underlying pathophysiological mechanisms, such as administering an analgesic to relieve pain in a subject, where the drug does not address the underlying cause of the pain. Beneficial effects of treatment include reducing the rate of disease progression, improving or alleviating the disease state, achieving symptom remission, or improving prognosis. For example, if one or more cancer-related symptoms are reduced or eliminated, the subject is considered to have received "treatment," which includes, but is not limited to: improving the quality of life of cancer patients, reducing the dosage of combination cancer drugs, delaying cancer progression, and prolonging the survival of the subject.

[0110] The term "cleavable linker" or "photocleavable linker" refers to a class of linker groups that can undergo cleavage or photocleavage under specific suitable conditions, such as light, acidic environment, hydrolysis conditions, and enzymatic conditions.

[0111] "alkyl radical" or "alkyl" refers to a group containing 1-20 carbon atoms, 1-10 carbon atoms, or 1-8 carbon atoms. Alkyl groups can be straight-chain or branched, and their carbon chains can optionally be separated by one or more heteroatoms (such as nitrogen, oxygen, or sulfur). Heteroatoms can be connected to hydrogen substituents and / or any permitted substituents of the organic compound to satisfy the valence balance of the heteroatom. Alkyl groups can optionally be modified by one or more of the aryl groups described above; one or more aryl groups can also be attached to the alkyl structure, with applicable aryl types as described above. Exemplary alkyl groups include, but are not limited to: methyl, ethyl, isopropyl, n-propyl, isobutyl, n-butyl, tert-butyl, sec-butyl, isopentyl, n-pentyl, sec-pentyl, neopentyl, n-hexyl, isohexyl, and sec-hexyl.

[0112] As used herein, “substituted” refers to all compliant substitutions of the compounds or functional groups described in this document. Exemplary substituents include, but are not limited to, halogens, hydroxyl groups, or any carbon-containing organic group (preferably 1-14 carbon atoms), which may optionally contain one or more heteroatoms (such as oxygen, sulfur, nitrogen) and exist in a straight-chain, branched, or cyclic structure. Representative substituents include: alkyl, substituted alkyl (such as -CF3 and -CD3), alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, substituted phenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, halogen, hydroxyl, alkoxy, formyl, substituted alkoxy, phenoxy, substituted phenoxy, aryloxy, substituted aryloxy, mercapto (-SH), substituted mercapto, arylthio, substituted arylthio, cyano, isocyano, substituted isocyano, carbonyl, substituted carbonyl, carboxyl, substituted carboxyl, carboxyl ester, amino, substituted amino, amide, substituted amide, sulfonyl, substituted sulfonyl, sulfonic acid, phosphoryl, substituted phosphoryl, phosphonyl, substituted phosphonyl, polyaryl, substituted polyaryl, cycloalkyl (such as C3-C) 20 Cycloalkyl), substituted cycloalkyl (such as substituted C3-C) 20 Cycloyl, heterocyclic, substituted heterocyclic, deuterium, trihaloalkyl (trifluoromethyl), non-substituted diarylamino, substituted diarylamino, non-substituted dialkylamino, substituted dialkylamino, azo, carbonate, nitro, nitroso, phosphinyl, pyridyl, NRR', SR, C(O)R, COOR, C(O)NR, SOR and SOR groups, wherein R and R' are each independently selected from hydrogen atoms, deuterium atoms or any of the above substituents.

[0113] The numerical range discloses individually every possible number that such a range can reasonably cover, as well as any sub-ranges and combinations thereof. For example, in a given concentration range of 10 μM to 500 μM, the range also discloses 20 μM, 33 μM, 350 μM, and 499 μM, as well as any sub-ranges between these numbers (e.g., 50 μM to 250 μM), and any possible combinations of possible ranges between these values.

[0114] The term “about” is used to describe values ​​that are higher or lower than the specified value modified by the term “about”, which is in the range of approximately + / - 10%. When the term “about” is used before a series of numbers (i.e., about 1-5) or before a series of numbers (i.e., about 1, 2, 3, 4, etc.), unless otherwise stated, it is intended to modify each number listed at either end of the range of numbers and / or throughout the series.

[0115] II. Multifunctional BODIPY photocage and its pharmaceutical composition

[0116] This paper describes a therapeutic strategy for achieving photoactivated combination therapy (PCT) based on near-infrared light-responsive BODIPY photocages, such as NI2Me2BO-OH (NIBO). This photocage can generate… 1 O2 (Type II PDT), O2 ·- BODIPY-based photocages, containing OH· (type I PDT), release a loading medium, such as a drug molecule or associated polyethylene glycol, upon irradiation with near-infrared light to provide combined tumor therapy. Therefore, such photocages represent “multifunctional” photocages that allow single-agent-based PCT by releasing the drug and generating type I and type II PDTs upon exposure to near-infrared light. The photoactivated combination effect can enhance treatment outcomes and eliminate tumor growth and recurrence in cancer subjects. As described herein, different types of BODIPY-based photocages have been prepared using different types of loading media, including but not limited to the chemical drug RG108 and poly(ethanol) groups (PEGs). The resulting BODIPY-based prodrugs and nanocarriers have demonstrated anticancer PCT efficacy against various types of cancers and tumors associated with esophageal squamous cell carcinoma, colon cancer, and melanoma.

[0117] A.BODIPY light cage

[0118] In some embodiments, the photocage compound includes a reactive functional (i.e., cleavable) group suitable for binding a support (i.e., a drug) and has the structure shown in Formula I:

[0119] Wherein, X is selected from hydrogen or halogen (e.g., iodine, bromine, chlorine) and at least one X group is not hydrogen;

[0120] R1-R5 are each independently selected from hydrogen, C1-C6. 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and at least one of the R1-R5 substituents is not hydrogen;

[0121] R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and R6-R 10 At least one of the substituents is not hydrogen;

[0122] R 11 R 13 Each is independently selected from C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0123] R 12The R” is a cleavable group selected from –OH, –SH, –NH2, or –NHR”; wherein R” is C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0124] R 14 R 15 Each is independently selected from halogens (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 );and

[0125] R 16 R 17 Each is independently selected from hydrogen, C1-C 10 Alkyl groups (e.g., methyl, ethyl).

[0126] Preferably, both X are iodine (i.e., dihalogenated). However, in other embodiments, only one X is a halogen atom such as iodine, while the other X is a hydrogen atom, and thus the photocage is NI1Me2BO-OH (i.e., monohalogenated).

[0127] In some embodiments, R3 and / or R8 are alkoxy or dialkyl-substituted amino groups (e.g., methoxy, ethoxy, butoxy, dimethylamino, diethylamino, or diisopropylamino), and R1-R2, R4-R5, R6-R7, and R9-R 10 It is hydrogen. In some implementations, R 14 and R 15 Each is independently a halogen (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 In some implementations, R 11 and R 13 It can be methyl or ethyl.

[0128] In some embodiments, the cleavable group is –OH, –SH, –NH2, or –NHR. Compounds of formula (I) may contain other suitable cleavable groups adapted to complementary reactive groups on the surface of the drug or PEG; the drug or PEG is intended to be coupled to the compound via the cleavable group. Such groups are well known to those skilled in the art and can constitute cleavable linkers. Cleavable means that the linker can break under specific conditions. In some embodiments, the photocage compound has one of the following structures:

[0129] 1. Generation of reactive oxygen species (ROS)

[0130] Studies have found that halogenation, particularly iodination, can promote the generation of reactive oxygen species by reducing fluorescence relaxation and enhancing intersystem crossings, while maintaining the photoactivation capability of the photocage.

[0131] As mentioned earlier, BODIPY light cages can produce 1 O2 (Type II PDT), O2 ·- And OH· (type I PDT), and release the loaded material, such as a cleavable drug or associated polyethylene glycol. In some cases, the photocage exhibits high singlet oxygen (OH·) at 656 nm light. 1 O2) Yield (φ[ 1 O2 (62.5%) and efficient cargo release performance. In most cases, the light cage not only produces 1 O2 also produces superoxide (O2 · The presence of hydroxyl radicals (OH·) and other substances indicates their applicability for type I / II photodynamic therapy (PDT).

[0132] In some embodiments, the photocage of formula I-II exhibits at least about 55% to 65% or 58% to 62%, or about 62% or higher high singlet oxygen content. 1 O2) Quantum Yield (φ[ 1 O2].

[0133] In some embodiments, for photocages of formulas I-II, R3 and / or R8 are electron-donating groups, such as -OR", where R" is a C1-C8 alkyl group (e.g., methyl, ethyl, or butyl), and R1-R2, R4-R5, R6-R7, and R9-R 10 It is hydrogen.

[0134] In some embodiments, R3 and / or R8 can be other electron-donating groups, such as dialkyl-substituted amino groups, for example -N(R”')2, wherein each R”' is selected from C1-C8 alkyl groups (dimethylamino, diethylamino, diisopropylamino). The presence of such electron-donating groups at specific positions can be used to generate an enhanced type I PDT effect, producing superoxide (O2) in addition to type II singlet oxygen. ·- ) and hydroxyl radicals (OH·). "Electron-donating groups" generally refer to functional groups that increase electron density by donating electrons through, for example, inductive effects (+I) or resonance effects (+R), such as the non-limiting exemplary groups discussed above. Other electron-donating groups may be used in addition to those listed herein.

[0135] Various ROS can be detected and identified using any suitable method. For example:

[0136] 1O2 detection: can be achieved by monitoring exposure to, for example, 656nm radiation (1mW / cm²). 2 The oxidation of 1,3-diphenylisobenzofuran (DPBF) by photocage aqueous solution at different time intervals was detected. 1 O2 generation. Record and analyze the absorbance changes of DPBF at a wavelength of 420 nm. Repeat the experiment three times under each condition.

[0137] OH· Detection: The generation of OH· can be detected using, for example, hydroxyphenyl fluorescein (HPF). An aqueous photocage solution mixed with HPF is exposed to, for example, 656 nm irradiation (10 mW / cm²). 2 Different time periods. The rate of OH· production will be determined by measuring, for example, the fluorescence intensity at 514 nm. The experiment was repeated three times for each set of conditions.

[0138] O2 ·- Detection: O2 ·- The generation of [a substance] can be detected using, for example, dihydrorhodamine (DHR). An aqueous solution of a photocage mixed with DHR is exposed to, for example, 656 nm irradiation (10 mW / cm²). 2 Different time periods were used. The emission spectrum was recorded approximately every 30 seconds, with an excitation wavelength of 505 nm. Each set of conditions was repeated three times.

[0139] In some embodiments, the photocage of formula I-II exhibits a fluorescence quantum yield of approximately 0.02 (Φ f ).

[0140] The ROS properties of the photocages apply to photocages of Formula I and II. Unbound by any particular theory, for BODIPY-based photocages as described herein, combinations of features such as alkylation (i.e., methylation) of boron, halogenation (i.e., iodination) of the BODIPY core, and extension of its π-backbone can produce NIR BODIPY photocages with both Type I (oxygen-independent) and Type II (oxygen-dependent) PDT effects, without reducing the photolysis efficiency of the photocage in the presence of a coupled support.

[0141] B.BODIPY light cage

[0142] As previously mentioned, a BODIPY photocage (as shown in Formula I above) is suitable for attaching a loading medium, such as a drug. In a non-limiting example, the photocage prodrug compound may have the structure of Formula II:

[0143] Wherein, D is a cleavable drug structural unit containing a photocleavable linker;

[0144] Each X is independently selected from halogens (e.g., iodine, bromine, chlorine);

[0145] R1-R5 are each independently selected from hydrogen, C1-C6. 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and at least one of the R1-R5 substituents is not hydrogen;

[0146] R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and R6-R 10 At least one of the substituents is not hydrogen;

[0147] R 11 R 13 Each is independently selected from C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0148] R 14 R 15 Each is independently selected from halogens (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 );and

[0149] R 16 R 17 Each is independently selected from hydrogen, C1-C 10 Alkyl groups (e.g., methyl, ethyl).

[0150] In some embodiments, the photocage prodrug compound may have the structure of formula II':

[0151] Where L is –O–, –S– or –NH–;

[0152] D represents a cleavable drug structural unit containing a photocleavable linker;

[0153] Each X is independently selected from halogens (e.g., iodine, bromine, chlorine);

[0154] R1-R5 are each independently selected from hydrogen, C1-C6. 10 Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and at least one of the R1-R5 substituents is not hydrogen;

[0155] R6-R 10 Each is independently selected from hydrogen, C1-C 10Alkoxy groups (e.g., methoxy, ethoxy, butoxy), dialkyl-substituted amino groups (e.g., –NMe2, –NEt2, –NiPr2), and R6-R 10 At least one of the substituents is not hydrogen;

[0156] R 11 R 13 Each is independently selected from C1-C 10 Alkyl groups (e.g., methyl, ethyl);

[0157] R 14 R 15 Each is independently selected from halogens (e.g., F), C1-C 10 Alkyl (e.g., methyl, ethyl) or C1-C 10 Alkoxy groups (i.e., -OR, e.g. -OC1 to -OC) 10 );and

[0158] R 16 R 17 Each is independently selected from hydrogen, C1-C 10 Alkyl groups (e.g., methyl, ethyl).

[0159] It should be understood that the photosplittable linker is usually the linker point to the BODIPY core.

[0160] Preferably, each X is iodine. In some embodiments, R3 and / or R8 are alkoxy or dialkyl-substituted amino groups (e.g., methoxy, ethoxy, butoxy, dimethylamino, diethylamino, or diisopropylamino), and R1-R2, R4-R5, R6-R7, and R9-R 10 It is hydrogen. In some implementations, R 14 and R 15 It is methyl or ethyl. In some embodiments, R 11 and R 13 It can be methyl or ethyl.

[0161] It should be understood that the photolytically cleavable linker is typically a linker to the BODIPY core. For example, the photolytically cleavable portion may be or may include an ester group (-OC(O)-).

[0162] For the drug moiety associated with the BODIPY core, there are no particular limitations on the drug moiety that can be coupled via the cleavable group of Formula I above, based on the selection of a drug having a suitable complementary reactive (cleavable) group thereon. Without limitation, the cleavable drug moiety D of Formula II or II' can have one of the following structures:

[0163] For the cleavable drug portion D shown above, when the photocage has the structure of formula II', the carboxyl oxygen can be replaced by -S- or -NH-.

[0164] In some embodiments, the photocage prodrug compound of formula II has one of the following structures:

[0165] C. Pharmaceutical Composition

[0166] In some embodiments, a multifunctional BODIPY photocage of formula I-II as described herein constitutes part of the pharmaceutical composition.

[0167] The pharmaceutical composition comprises an effective amount of a multifunctional BODIPY photocage and optionally one or more pharmaceutically acceptable carriers and / or excipients.

[0168] In one non-limiting example, the pharmaceutical composition comprises: a photocage prodrug compound of formula II; and at least one pharmaceutically acceptable carrier.

[0169] In some embodiments, the pharmaceutical composition comprises: a plurality of photocage PEG compounds; and at least one pharmaceutically acceptable carrier; wherein the plurality of photocage PEG compounds form a self-assembled nanocarrier (e.g., nanoparticles). The self-assembled nanocarrier (e.g., nanoparticles) may carry a payload or loading material encapsulated therein, such as a drug.

[0170] In some embodiments, the one or more pharmaceutically acceptable carriers are selected from water, ethanol, polyethylene glycol, propylene glycol, deacetylated chitosan polymers and deacetylated chitosan derivatives (e.g., N-chloroform deacetylated chitosan, deacetylated chitosan esters, deacetylated chitosan modified with hydrophilic groups such as amino, carboxyl, sulfate groups, etc.), methylcellulose, oils, and combinations thereof. Other suitable carriers are known.

[0171] The pharmaceutical composition comprises an effective amount of a multifunctional BODIPY photocage for treating diseases or conditions, such as cancer. In some embodiments, the multifunctional BODIPY photocage is present at concentrations of about 1 μM to about 1 mM, about 10 μM to about 500 μM, about 10 μM to about 200 μM, or about 25 μM to about 100 μM of the pharmaceutical composition, and various values ​​and subranges within the aforementioned ranges. In some other cases, the multifunctional BODIPY photocage is present at concentrations of about 1 μM to about 10 mM, about 1 μM to about 5 mM, about 10 μM to about 1 mM, or about 10 μM to about 500 μM of the pharmaceutical composition, and various values ​​and subranges within the aforementioned ranges. Other concentrations are also possible.

[0172] In some embodiments, depending on the route of administration, the effective amount of the multifunctional BODIPY photocage in the composition can be 0.01 to 1000 mg, 0.1 to 500 mg per kilogram of body weight per day for the subject, for example, 1 to 250 mg, such as about 5, 10, 20, 50, 100, 150, 200, or 250 mg per kilogram of body weight per day for the subject. It can be administered as a single daily dose, divided into one or more daily doses. Other doses are also possible. The dosage, route of administration, and further treatment regimen of the multifunctional BODIPY photocage can be determined by the treating clinician or testing technology, depending on factors such as the subject's age, sex, and general condition, the nature and severity of the disease / symptom to be prevented, treated, or diagnosed, and / or the sample to be tested.

[0173] Also provided are pharmaceutical compositions comprising a therapeutically effective amount of the aforementioned multifunctional BODIPY photocage, and optionally one or more additional therapeutic, preventative, and / or diagnostic agents. The pharmaceutical compositions can be administered via parenteral (intramuscular, intraperitoneal, intravenous (IV), or subcutaneous), enteral, or mucosal (intranasal, vaginal, rectal, or sublingual) routes of administration, or using bio-erosion inserts, and can be formulated into dosage forms suitable for each route of administration.

[0174] 1. Parenteral composition

[0175] Pharmaceutical compositions containing the aforementioned multifunctional BODIPY photocage can be administered via parenteral injection in the form of an aqueous solution. Such compositions can also be in the form of a suspension or emulsion. Typically, the provided pharmaceutical compositions comprise an effective amount of the active agent (i.e., the multifunctional BODIPY photocage), optionally including pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants, and / or carriers. Such compositions include diluents such as sterile water, buffered saline solutions with different buffering systems (e.g., Tris-HCl, acetate, phosphate), pH values, and ionic strengths; and optionally, additives such as detergents and solubilizers (e.g., [missing information]). 20. 80 (also known as polysorbate 20 or 80), antioxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., thimerosal, benzyl alcohol), and fillers (e.g., lactose, mannitol). Examples of non-aqueous solvents or media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. The composition can be lyophilized and reconstituted / resuspended immediately before use. The composition can be sterilized by, for example, filtering with a bacterial trap filter, incorporating a sterilizing agent into the composition, irradiating the composition, or heating the composition.

[0176] These specific aqueous solutions are particularly suitable for intranasal or intratracheal administration, such as through the respiratory tract. They are also suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this regard, sterile aqueous media that can be used according to this disclosure are known to those skilled in the art. For example, a unit dose can be dissolved in 1 mL of isotonic NaCl solution, and dose adjustments will necessarily occur according to the condition of the subject being treated. In any case, the person responsible for administration will determine the appropriate dose for the individual subject.

[0177] 2. Oral composition

[0178] Pharmaceutical compositions containing the aforementioned multifunctional BODIPY photocage can be provided in a form suitable for oral administration to subjects in need (e.g., mammals) (i.e., oral compositions). Oral administration may involve swallowing so that the multifunctional BODIPY photocage and optional additional active agents enter the gastrointestinal tract, or it may be administered orally or sublingually so that the multifunctional BODIPY photocage enters the bloodstream directly from the oral cavity.

[0179] Compositions suitable for oral administration include solid compositions, such as tablets, capsules containing particles, liquids, powders, lozenges (including liquid-filled lozenges), chewable tablets, multi-particle and nanoparticles, gels, solid solutions, liposomes, films, vaginal suppositories, sprays, and liquid compositions.

[0180] Liquid compositions for oral administration include suspensions, solutions, syrups, and elixirs. Such oral compositions can be used as fillers in soft or hard capsules and may contain one or more suitable carriers and / or excipients, such as water, ethanol, polyethylene glycol, ethylene glycol, chitosan polymers and chitosan derivatives (e.g., N-trimethylene chloride chitosan, chitosan esters, chitosan modified with hydrophilic groups such as amino, carboxyl, sulfate groups, etc.), methylcellulose, suitable oils, one or more emulsifiers, and / or suspending agents. Liquid compositions for oral administration can also be prepared, for example, by reconstitution of a solid in a sachet.

[0181] For tablet or capsule dosage forms, in addition to the multifunctional BODIPY light cage described herein, tablets typically contain disintegrants, binders, diluents, surfactants, lubricants, flow aids, antioxidants, colorants, flavorings, preservatives, or taste masking agents, or combinations thereof.

[0182] Examples of suitable disintegrants for forming tablets or capsules containing a multifunctional BODIPY photocage include, but are not limited to, sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methylcellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinized starch, and sodium alginate. Generally, the concentration of the disintegrant can be from about 1 wt% to about 25 wt%, or from about 5 wt% to about 20 wt% of the tablet or capsule containing the multifunctional BODIPY photocage.

[0183] Binders are commonly used to impart adhesive properties to tablet compositions containing multifunctional BODIPY light cages. Suitable binders for forming tablet or capsule formulations may include, but are not limited to, microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinized starch, deacetylated chitosan polymers and deacetylated chitosan derivatives (e.g., N-chloroform deacetylated chitosan, deacetylated chitosan esters, deacetylated chitosan modified with hydrophilic groups such as amino, carboxyl, sulfate groups, etc.), hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

[0184] Suitable diluents for forming tablet or capsule compositions containing multifunctional BODIPY photocages may include, but are not limited to, lactose (e.g., monohydrate, spray-dried monohydrate, or anhydrous form), chitosan polymers and chitosan derivatives (e.g., N-chloroform chitosan, chitosan esters, chitosan modified with hydrophilic groups such as amino, carboxyl, sulfate groups, etc.), N-sulfonated chitosan derivatives, chitosan quaternized derivatives, carboalkylated chitosan, microcrystalline chitosan, mannitol, xylitol, glucose, sucrose, sorbitol, microcrystalline cellulose, starch, and dicalcium phosphate dihydrate.

[0185] Tablet or capsule compositions containing a multifunctional BODIPY light cage may also contain surfactants, such as sodium dodecyl sulfate and polysorbate 80, and flow aids, such as silica and talc, in the coating.

[0186] When present, the concentration of the surfactant can be from about 0.2 wt% to 5 wt% of the tablet or capsule formulation.

[0187] Tablet or capsule compositions containing a multifunctional BODIPY light cage typically also contain lubricants, such as magnesium stearate, calcium stearate, zinc stearate, sodium stearoyl fumarate, and mixtures of magnesium stearate and sodium dodecyl sulfate. The concentration of the lubricant can range from about 0.25 wt% to 10 wt%, or from about 0.5 wt% to about 3 wt% of the tablet or capsule composition.

[0188] Other possible excipients contained in tablet or capsule formulations containing a multifunctional BODIPY light cage include flow aids (e.g., about 0.1 wt% to about 3 wt% of talc or colloidal anhydrous silica in the tablet or capsule formulation), antioxidants, colorants, flavoring agents, preservatives, and taste masking agents. When present, flow aids may be present at concentrations ranging from about 0.2 wt% to 1 wt% of the tablet or capsule composition.

[0189] Tablet or capsule mixtures comprising a multifunctional BODIPY light cage and one or more suitable excipients can be directly compressed or roller-compressed into tablets. Alternatively, the tablet or capsule mixture, or a portion thereof, can be wet-granulated, dry-granulated, melt-coated, or extruded prior to tableting. The final tablet or capsule composition may comprise one or more layers and may be coated or uncoated; it may even be encapsulated in granules, such as polymer granules or liposome granules.

[0190] Solid dosage forms containing a multifunctional BODIPY photocage for oral administration can be formulated for immediate release and / or modified release. Modulated release formulations include delayed release, sustained release, pulsatile release, controlled release, targeted release, and programmed release formulations.

[0191] 3. Optional therapeutic, preventative, or diagnostic agents.

[0192] In some embodiments, the pharmaceutical composition may optionally contain one or more additional active agents. Thus, in some embodiments, in addition to at least one of a therapeutic agent, a preventative agent, and / or a diagnostic agent, the pharmaceutical composition also includes a multifunctional BODIPY photocage. The additional active agent may be used in combination with the multifunctional BODIPY photocage or may be used in combination as a standalone composition. In some embodiments, when the pharmaceutical composition contains a nanocarrier (nanoparticle) formed by the self-assembly of multiple photocage compounds, the additional active agent, such as a therapeutic agent, preventative agent, or diagnostic agent, may be encapsulated by the nanocarrier (nanoparticle) and may be released therefrom upon NIR irradiation.

[0193] Non-limiting examples of therapeutic, preventative, or diagnostic agents may include bronchodilators, corticosteroids, methylxanthine, phosphodiesterase-4 inhibitors, anti-angiogenic agents, antibiotics, antioxidants, antiviral agents, antifungal agents, anti-inflammatory agents, immunosuppressants, anti-allergic agents, photosensitizers, and combinations thereof. The amount of any additional therapeutic, preventative, or diagnostic agent generally depends on the severity of the disease and / or condition to be treated.

[0194] In some embodiments, the anti-angiogenic agent includes colchicine (e.g., N-acetylcolchicine and colchicine prodrugs, such as N-acetylcolchicine-O-phosphate), compressines (e.g., compressine A1 and A4 and their prodrugs, including compressine A4 phosphate, compressine A1 bisphosphate, crolibulin, and AVE8062), and TNP-470.

[0195] In some embodiments, the photosensitizer includes cyanide dye molecules such as IR-780, IR-783, IR-808, IR-775, IR-797, IR-820, IR-1048, IR-1061, IR-27, and IR-806.

[0196] In some embodiments, the photosensitizer and the anti-angiogenic agent are linked by a linking group to form an NIR photoactivated prodrug; this type of NIR photoactivated prodrug can release the anti-angiogenic agent under NIR light activation.

[0197] In some embodiments, the NIR photoactivated prodrug comprises the following compounds:

[0198] Those skilled in the art can readily determine the specific dosage. See Ansel, Howard C. et al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th ed.) Williams and Wilkins, Malvern, PA (1995).

[0199] 4. Pharmaceutically acceptable carriers and excipients

[0200] The pharmaceutical composition may be formulated with one or more excipients and / or carriers suitable for the specified route of administration. In some embodiments, the multifunctional BODIPY photocage is formulated in a manner suitable for treating human and / or animal subjects. In some embodiments, the pharmaceutical composition comprises mixing or combining the multifunctional BODIPY photocage with one or more of the following excipients: lactose, sucrose, starch powder, cellulose esters of carboxylic acids, alkyl cellulose esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric acid and sulfuric acid, gelatin, gum arabic, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol. In some embodiments, for example for oral administration, the pharmaceutical composition may be formulated as tablets or capsules. In some embodiments, the multifunctional BODIPY photocage may be slurried in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and / or various buffer solutions. In some embodiments, the pharmaceutical composition may be subjected to pharmaceutical processing, such as sterilization; and / or may contain carriers and / or excipients, such as preservatives, stabilizers, wetting agents, emulsifiers, encapsulating agents such as lipids, dendritic polymers, polymers, proteins such as albumin, nucleic acids, and buffers.

[0201] 5. Dosage Form

[0202] In some embodiments, it may be advantageous to formulate the pharmaceutical composition in unit dosage form to facilitate administration and uniformity of dosage. As used herein, “unit dosage form” refers to a physically discrete unit suitable as a single dose to a patient to be treated; each unit contains a predetermined amount of therapeutic agent (i.e., a multifunctional BODIPY photocage) that is calculated to bind with a drug carrier to produce the desired therapeutic effect. In some embodiments, the specification of the unit dosage form depends on and is directly dependent on (a) the unique properties of the therapeutic agent and the specific therapeutic effect to be achieved, and (b) the inherent limitations of the field when formulating such a therapeutic agent for the treatment of a patient’s target condition. In some embodiments, the multifunctional BODIPY photocage is administered at a therapeutically effective dose sufficient to treat a condition associated with the patient’s condition, such as cancer. For example, the efficacy of a pharmaceutical composition containing a multifunctional BODIPY photocage can be evaluated in an animal model system that can predict efficacy in treating diseases in humans or another animal.

[0203] In some embodiments, the appropriate dose or therapeutically effective dose range of the combination is from 0.001 to 500 mg per kilogram of body weight per day for the recipient (e.g., about 1 μg to about 500 mg per kilogram of body weight, about 100 μg to about 100 mg per kilogram of body weight, about 1 mg to about 75 mg per kilogram of body weight, about 10 μg to about 50 mg per kilogram of body weight, or about 1 μg to about 50 μg per kilogram of body weight).

[0204] In some implementations, the effective dose range of the therapeutic agent can be inferred from effective doses determined in animal studies of various animals. The precise amount of a pharmaceutical composition depends on the practitioner's judgment and varies from person to person. Other factors affecting dosage include the subject's physical and clinical condition, route of administration, intended therapeutic goals, and the potency, stability, and toxicity of the specific pharmaceutical composition.

[0205] The actual dose of the pharmaceutical composition of this disclosure administered to a subject can be determined by physical and physiological factors, such as the type of animal treated, age, sex, weight, severity of the condition, type of condition treated, prior or concurrent treatment interventions, patient specificity, and route of administration. These factors can be determined by a skilled technician. The practitioner responsible for administration will typically determine the concentration of the active agent in the composition and the appropriate dose for the individual subject. If any complications occur, a private physician may adjust the dose.

[0206] Single- or multi-dose active agents, such as the multifunctional BODIPY photocage, are considered. The required time intervals for delivering multiple doses can be determined by those skilled in the art using only routine experiments. As an example, a patient may be given two doses daily at approximately 12-hour intervals. In some embodiments, the agent is administered once daily.

[0207] The pharmaceutical composition can be administered according to a regular schedule. As used herein, a regular schedule refers to a predetermined, specified period of time. A regular schedule can cover the same or different periods of time, provided the schedule is predetermined. For example, a regular schedule can involve administration twice daily, once daily, once every two days, once every three days, once every four days, once every five days, once every six days, once weekly, once monthly, or any set number of days or weeks thereof. Alternatively, a predetermined routine schedule could involve administration twice daily for the first week, followed by once daily for several consecutive months, and so on. In some embodiments, the invention specifies that the medication can be administered orally, and the timing may depend on or not on food intake. Thus, for example, the medication can be taken every morning and / or every evening, regardless of when the patient has eaten or is about to eat.

[0208] In some embodiments, the pharmaceutical composition may be a unit dosage form that can be suitably packaged, such as a box, blister pack, vial, bottle, sachet, ampoule, or any other suitable single-dose or multi-dose holder or container (which may be suitably labeled); optionally accompanied by one or more leaflets containing product information and / or instructions for use. Generally, such unit doses may contain 1 to 1000 mg, or 5 to 500 mg, of the disclosed multifunctional BODIPY light cage, for example, about 10, 25, 50, 100, 200, 300, or 400 mg per unit dose.

[0209] E. Preparation method of multifunctional BODIPY light cage

[0210] Various BODIPY light cages and their multifunctional variants, such as Formulas I-II, can be prepared according to the non-limiting exemplary synthetic methods described in the following examples. Non-limitingly, those skilled in the art of synthetic chemistry can, at their discretion, change or modify the synthetic conditions (i.e., solvent selection, temperature (e.g., to achieve reflux), atmosphere, post-treatment conditions, purification conditions, etc.) from those discussed and exemplified herein without affecting the synthesis. The method may include additional steps that may be involved in the synthesis, not otherwise specified, including but not limited to product precipitation, washing of the reaction mixture, extraction of the reaction mixture, separation of the product from the mixture (e.g., by filtration), drying of the product, and combinations thereof. Further processing steps that may be involved include stirring, heating, and / or cooling of the reaction mixture. Intermediate products, crude products, and purified products can be characterized using any suitable characterization methods known to those skilled in the art. In some embodiments, such methods include, but are not limited to, […]. 1 H and 13 C NMR, mass spectrometry, elemental analysis or other techniques.

[0211] In some embodiments, a multifunctional BODIPY photocage is prepared from a compound of Formula I by coupling a drug or PEG to the drug or PEG via a suitable coupling reaction between a cleavable group (e.g., -OH, -SH, -NH2, or -NHR") and a complementary reactive group (e.g., a carboxylic acid). For example, a non-limiting coupling reaction could be an esterification reaction (i.e., DCC and DMAP) to form a cleavable ester group.

[0212] Those skilled in the art are aware of other suitable coupling reactions, cleavable groups, and complementary reactive groups that may be present on compounds of Formula I and pharmaceuticals or PEGs to form cleavable linkers other than esters.

[0213] III. Methods using multifunctional BODIPY light cages and their pharmaceutical compositions

[0214] The multifunctional BODIPY photocages described herein can be used in a variety of medical applications. For example, they can be used for photoactivated combination therapy (PCT) by inducing the release of various therapeutic agents (e.g., ROS and drugs) through near-infrared light irradiation. Examples demonstrate the photoactivated anticancer efficacy of various BODIPY photocage prodrugs and nanocarriers against various types of tumors.

[0215] In a non-limiting context, the multifunctional BODIPY light cage can be used in a method for photoactivated combination therapy (PCT), comprising the following steps:

[0216] (i) administering a pharmaceutical composition comprising the multifunctional BODIPY photocage described herein to a subject in need; and

[0217] (ii) Irradiate the photocage prodrug compound of the pharmaceutical composition with a sufficient dose of light (e.g., near-infrared light) to generate reactive oxygen species (ROS) and induce photolysis and release of at least some of the cleavable drug fractions.

[0218] In some embodiments, the light is near-infrared (NIR) light and optionally has a wavelength range from about 650 nm to 900 nm, and various values ​​or sub-ranges thereof. In some embodiments, the light has a wavelength of about 1 mW / cm². 2 Up to 500mW / cm 2 1mW / cm 2 Up to 250mW / cm 2 1mW / cm 2 Up to 100mW / cm 2 1mW / cm 2 Up to 50mW / cm 2 1mW / cm 2 Up to 500mW / cm 2 1mW / cm 2 Up to 250mW / cm 2 1mW / cm 2 Up to 100mW / cm 2 1mW / cm 2 Up to 50mW / cm 2 1mW / cm 2 Up to 25mW / cm 2 or 1mW / cm 2 Up to 10mW / cm 2 Output intensity within the range of; or approximately 1 mW / cm 2 10mW / cm 2 20mW / cm 2 30mW / cm 2 40mW / cm 2 50mW / cm 2 60mW / cm 2 70mW / cm 2 80mW / cm 2 90mW / cm 2 Or 100mW / cm 2 The output intensity can be measured from a given distance (e.g., 1 cm) from the source providing (NIR) light.

[0219] In some embodiments, the duration of light irradiation ranges from about 0.1 seconds to 15 seconds, 0.01 seconds to 15 minutes, 0.01 seconds to 10 minutes, 0.01 seconds to 5 minutes, 0.01 seconds to 2.5 minutes, or 0.01 seconds to 1 minute; or at least about 0.01 seconds, 10 seconds, 15 seconds, 1 minute, 2.5 minutes, 5 minutes, 10 minutes, or 15 minutes.

[0220] In some embodiments, the subject has cancer (e.g., esophageal squamous cell carcinoma, colon cancer, or melanoma). In some embodiments, the pharmaceutical composition is administered to the subject's tumor. In some embodiments, the pharmaceutical composition is administered to the subject via intranasal administration, oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, or a combination thereof.

[0221] In some embodiments, the photocage prodrug compound of the pharmaceutical composition is present after steps (i) and (ii) to effectively treat, inhibit, and / or reduce the concentration of cancer or tumor.

[0222] In some embodiments, the method further includes co-administering one or more therapeutic, preventative, or diagnostic agents to the subject. Exemplary therapeutic, preventative, or diagnostic agents have been described above.

[0223] In some embodiments, the use of a multifunctional BODIPY photocage or pharmaceutical composition in the preparation of a tumor-treating drug.

[0224] In some embodiments, the treatment includes photoactivated combination therapy.

[0225] IV. Treatment System

[0226] The multifunctional BODIPY light cage described in this article can be used in conjunction with a PDT device.

[0227] In some embodiments, the PDT device includes a non-implantable laser therapy device or an implantable fiber optic therapy device; wherein, the multifunctional BODIPY light cage and the implantable fiber optic therapy device are combined to form an implantable fiber optic therapy system to achieve in situ local treatment of cancer.

[0228] In some embodiments, a non-implantable laser therapy device is included; the non-implantable laser therapy device includes a power supply, a laser generator, and a light guide assembly.

[0229] In some embodiments, the implantable fiber optic device includes a laser source, a catheter, and fiber optic components (such as fiber optic cannulas); a photocage prodrug compound or drug composition is delivered to the tumor site via the catheter, followed by NIR light irradiation.

[0230] In some implementations, one or more optical fibers are used to conduct NIR light.

[0231] In some implementations, one or more optical fibers are in separate conduits within the device or can be coupled to device-to-device conduits.

[0232] In some embodiments, the optical fiber is in a common lumen, wherein the optical fiber is in the lumen of a catheter that also delivers a photocage prodrug compound or pharmaceutical composition.

[0233] In some implementations, the optical fiber extends along the length of the catheter and is controlled by a deployment handle assembly. The distal end of the optical fiber is located near, at, or away from the distal end of the catheter to allow the user to deliver NIR light to the target area after delivery of a photocage prodrug compound or drug composition.

[0234] In some implementations, the optical fiber is connected to a laser source located outside the conduit and cooperating with a selected connection device.

[0235] In some implementations, flexible optical fibers can be easily inserted into the patient's body using, for example, manipulable devices such as endoscopes, bronchoscopes, gavage needles, etc.

[0236] In some implementations, the treatment system also includes imaging devices, such as in vivo animal imaging systems (e.g., IVIS Lumina III, IVIS Kinetic, and FPRO).

[0237] The methods, compounds, and compositions described herein are further illustrated in the following examples, which are provided by way of illustration and are not intended to be limiting. It should be understood that variations in the proportions of the elements of the illustrated components and alternatives will be apparent to those skilled in the art and are within the scope of the disclosed forms. Unless otherwise stated, all parts or quantities are by weight.

[0238] Example

[0239] Example 1: NIR Multifunctional BODIPY Optical Cage

[0240] This embodiment relates to the development and use of a multifunctional near-infrared (NIR) light-absorbing boron-dipyrrole methylene (BODIPY) photocage (NI2Me2BO-OH, NIBO), which exhibits high reactive oxygen species (ROS) yield and loading release capability, and can be used for photoactivated combination tumor therapy.

[0241] Materials and Methods:

[0242] Chemicals, solvents, and consumables:

[0243] N,N-Diisopropylethylamine, DPBF, DHR 123, and HPF were purchased from Sigma-Aldrich (Steinheim, Germany). All other chemicals used were obtained from J&K Scientific (Beijing, China). Dichloromethane, N,N-dimethylformamide, dimethyl sulfoxide, acetonitrile, methanol, hexene, ethyl acetate, tetrahydrofuran, and other organic solvents were purchased from Oriental (Hong Kong, China). Dialysis bags with molecular weight cutoffs ranging from 500 to 10,000 were obtained from Thermo Fisher (Heysham, Lancashire, UK). All antibodies were purchased from Abcam (Cambridge, UK). All consumables used for Western blot assays were supplied by Bio-Rad Laboratories (California, USA). Thin-layer chromatography plates (F254, silica gel 60) were supplied by Labware (Hong Kong, China). Silica gel columns were purchased from Teledyne ISCO (Lincoln, USA). Glassware was purchased from Synthware (Beijing, China).

[0244] Synthesis of NIR BODIPY light cages:

[0245] Compound 1: This molecule was synthesized by a modified method reported in a previous study (JA Peterson et al., Family of BODIPY Photocages Cleaved by Single Photons of Visible / Near-Infrared Light. J. Am. Chem. Soc. 140, 7343-7346 (2018)). Briefly, 25 mg (0.078 mmol, 1 eq) of racemic methyl BODIPY-OAc was dissolved in 500 μL of p-anisaldehyde (preheated to 60-70 °C). The reaction was monitored by colorimetry of the mixture, which changed from orange to deep blue within 5-10 minutes. The residue was rapidly cooled to 0 °C in an ice bath, and the product was identified by TLC (rf = 0.5, DCM / hexene = 1:1). Purification was performed by silica gel column chromatography (DCM / hexene = 1:1) in 92.5% yield. 1 H NMR(400MHz, DMSO-d6)δ7.61–7.53(m,4H),7.34(d,J=2.2Hz,4H),7.13–7.00(m,4H),6.97–6.87( m,2H),5.46(t,J=4.8Hz,1),4.80(d,J=4.7Hz,2H),3.82(s,6H),2.70–2.45(m,6H),0.37(s,6H).

[0246] Compound 2: 200 mg (0.36 mmol) of compound 1 was dissolved in DCM under a nitrogen atmosphere, 12 mL of 0.1 M sodium hydroxide MeOH solution was added, and the reaction was carried out for approximately 12 hours, monitored by TLC. The product was identified by TLC (rf = 0.5, DCM) and purified on a silica column (100% DCM) in 100% yield.

[0247] Compound 3: 50 mg (0.1 mmol) of compound 2 was dissolved in DCM under a nitrogen atmosphere, and 0.3 mL of 3M methyl magnesium bromide ethyl ester solution (10 eq) was added. The reaction was carried out for approximately 6 hours, monitored by TLC. The product was identified by TLC (rf = 0.7, DCM / hexene = 1:1) and purified on a silica gel column (0-50% DCM / hexene), yield = 45.0%.

[0248] Compounds 4 and 5: Compounds 4 and 5 are different products of the following reactions with iodide reagents in different proportions. Photocage 3 (50.6 mg, 0.1 mmol, 1 eq) was dissolved in a mixture of anhydrous tetrahydrofuran (2 mL) and hexene (2 mL). N-iodosuccinimide (20.1 mg, 0.09 mmol, 0.9 eq) was dissolved in anhydrous tetrahydrofuran (1 mL) and added dropwise to a flask under ice bath conditions. The solution was protected with N2 and stored in the dark. After 3.5 hours, an additional volume of 10 mL of hexene was added via syringe, and the solvent was then evaporated under vacuum in an ice bath. The residue was purified by silica gel column chromatography to a deep blue solid (4), TLC (rf = 0.55, DCM / hexene = 1:2), yield = 40.0%. 1 H NMR(400MHz,DMSO-d6)δ7.59(d,J=8.8Hz,5H),7.52(s,1H),7.40(s,1H),7.36(s,1H),7. 11–7.00(m,6H),5.56(t,J=5.0Hz,1H),4.78(d,J=4.7Hz,2H),3.83(s,6H),2.58(s,6H).

[0249] To obtain 5 (TLC (rf = 0.6, DCM / hexene = 1:2)), the process is similar, except that the amount of N-iodosuccinimide is changed to 73.7 mg (0.3 mmol, 3 eq), yield = 22.5%. 1¹H NMR (400MHz, DMSO-d⁶) δ 7.73 (d, J = 16.7Hz, 1H), 7.63–7.51 (m, 2H), 7.28 (d, J = 16.7Hz, 1H), 7.16–6.98 (m, 2H), 5.69 (d, J = 4.7Hz, 1H), 4.84 (d, J = 4.4Hz, 2H), 3.82 (s, 6H), 2.65 (s, 6H), 0.33 (s, 6H). LC-MS peaks: calculated m / z = 758.07, measured value 757.880.

[0250] Example 2: Synthesis of NIBO-based prodrugs:

[0251] Synthesis of NIRG prodrug:

[0252] Compound 5 (76 mg, 0.1 mmol, 1 eq), RG108 (or JQ-1 or Cb) (0.11 mmol, 1.1 eq), dicyclohexylcarbodiimide (DCC, 3 eq), and 4-dimethylaminopyridine (DMAP, 0.3 eq) were mixed in 5 mL of dry dichloromethane (DCM) and stirred overnight at room temperature in the dark. The solution was filtered to remove the precipitate, and then purified by HPLC in approximately 40% yield (by peak integration in HPLC). NIRG: 1 H NMR (400MHz, DMSO-d6) δ10.76(s,1H),7.95–7.71(m,4H),7.65–7.56(m,2H),7.49(d,J=7.9Hz,1H),7.33(s,3H),7.24(t,J= 9.2Hz,1H),7.12–6.81(m,6H),5.68–5.28(m,2H),5.12(dd,J=9.6,6.4Hz,1H),3.82(s,6H),2.41(s,6H),0.46–0.28(m,6H).

[0253] Synthesis of NIBO-JQ and NIBO-Cb prodrugs

[0254] Synthesis of IR820-CA4 prodrug and 820CA / NIRG nanoparticles:

[0255] Solution A: Combretastatin A-4 (CA4, 31.6 mg, 0.1 mmol, 1 eq.) and 4-nitrophenyl chloroformate (60.5 mg, 0.3 mmol, 3 eq.) were dissolved in 1 mL of anhydrous dichloromethane in a dry nitrogen-purged flask. The mixture was stirred overnight at room temperature. The reaction progress was monitored by thin-layer chromatography. Once the CA4 was completely consumed, no further purification was required, and the mixture was used directly for the next reaction.

[0256] Crude Product B: IR820 (127.4 mg, 0.15 mmol, 1.5 eq.) was dissolved in 1 mL of anhydrous DMF in a dry flask under nitrogen protection. A mixture of N-ethyldiisopropylamine (DIPEA, 0.15 mmol, 25.8 μL, 1.5 eq.) and N,N'-dimethylethylenediamine (DMA, 0.3 mmol, 29.4 μL, 3 eq.) was then added to the above solution. The mixture was stirred at 70 °C for approximately 5 minutes, and then immediately added dropwise to 200 mL of cold diethyl ether. The precipitate was collected by centrifugation (2000 g, 10 min) at 4 °C and dried in a vacuum desiccator. After confirming complete consumption of IR820 by high-performance liquid chromatography (HPLC), no further purification was required, and the product was used directly in the next reaction.

[0257] The crude product B was dissolved in 1 mL of anhydrous DMF and placed in a dry flask. Solution A was then slowly added dropwise to the above reaction mixture. After stirring the mixture for 24 hours, it was purified by high-performance liquid chromatography (HPLC) and lyophilized. The IR820-CA4 lyophilized powder was stored at -20°C protected from light.

[0258] Refer to Figure 19 for nanoparticle preparation:

[0259] 0.4 mg NIRG and 0.02 mg IR820-CA4 were dissolved in 5 μL DMSO and rapidly added dropwise to 0.4 mL under vortexing. The mixture was then centrifuged at 4000 g for 5 minutes to remove the precipitate. Afterwards, the solution was centrifuged at 3 × 10⁻⁶ ppm. 4 The nanoparticles were collected by centrifugation for 15 minutes and then redispersed in distilled water.

[0260] PDT effect evaluation:

[0261] 1 O2 detection: Detected by monitoring the oxidation of 1,3-diphenylisobenzofuran (DPBF). 1 O2 generation. Aqueous solutions of NBOF2-OH, NBOMe2-OH, NI1BOMe2-OH, NI2BOMe2-OH, and NIRG will be irradiated at 656 nm (1 mW / cm²). 2Exposure to different durations was performed. 1% final concentration (v / v) of DMSO was added to enhance the water solubility of DPBF. The absorbance change of DPBF at 420 nm was recorded and analyzed. Experiments under each condition were repeated three times.

[0262] OH· Detection: The formation of OH· was detected using hydroxyphenyl fluorescein (HPF). Aqueous solutions of NBOF2-OH, NBOMe2-OH, NI1BOMe2-OH, NI2BOMe2-OH, and NIRG were mixed with HPF and irradiated at 656 nm (10 mW / cm²). 2 Irradiation was performed for different durations. The rate of OH· production was determined by measuring the fluorescence intensity at 514 nm. The experiment was repeated three times for each condition.

[0263] O2 ·- Detection: O2 was detected using dihydrorhodamine (DHR). ·- The formation of NBOF2-OH, NBOMe2-OH, NI1BOMe2-OH, NI2BOMe2-OH and NIRG aqueous solutions were mixed with DHR and irradiated at 656 nm (10 mW / cm). 2 Irradiation was performed for different durations. The emission spectrum was recorded every 30 seconds, with an excitation wavelength of 505 nm. The experiment under each condition was repeated 3 times.

[0264] TD-DFT calculation:

[0265] Density functional theory (DFT) was used to optimize the ground state of NIBO. The calculations were performed using the Gaussian 16 software package. Geometric optimization was calculated using B3LYP / 6-31G(d)(LANL2DZ on I).

[0266] Quantitative HPLC analysis of unlysed NIRG and drug release:

[0267] To quantitatively determine uncleaved NIRG and released RG108, standard curves for these two molecules were first obtained by measuring a series of different concentrations of NIRG or RG108 using HPLC. Then, the signal integrals of NIRG or RG108 at different concentrations were linearly fitted to obtain standard curves, which were used to calculate the concentrations of NIRG and RG108 in subsequent HPLC measurements. Aqueous solutions of NIRG or RG108 were exposed to a 656 nm laser (100 mW / cm²). 2 Different time periods were observed, and then analyzed by HPLC. The experiment was repeated three times under each condition.

[0268] Cytotoxicity analysis:

[0269] Cytotoxicity was characterized using a CCK-8 assay. In short, cancer cells (KYSE-450, HCT116, CT26, B16F10, mEC25, etc.) were cultured at a primary density of 5000 cells / well in 96-well plates and incubated for 24 hours before adding the formulation. The medium was then replaced with medium containing different concentrations of the formulation. After 4 hours of incubation, the cells were washed three times with PBS and irradiated with light (656 nm, 100 mW / cm²). 2 NIBO and NIRG for 10 minutes, 730nm, 100mW / cm 2 (BP450 NP 10 min). Add 100 μL of CCK-8 solution to each well, incubate for 1 h, and then read the OD 450 to calculate cell viability.

[0270] Construction of a mouse model of orthotopic esophageal squamous cell carcinoma:

[0271] First, KYSE450 cells were transfected with the green fluorescent protein (GFP)-luciferase (luc) plasmid to obtain KYSE450-GFP-luc cells. The success of transfection was verified by detecting the fluorescence and bioluminescence of the resulting cells. Because the obtained KYSE450-GFP-luc cells exhibit strong fluorescence and bioluminescence, the survival and proliferation of tumor cells can be easily monitored using an in vivo imaging system (IVIS).

[0272] BALB / c nude mice (4 weeks old) were used for in situ inoculation. Prior to surgery, mice were anesthetized via intraperitoneal (ip) injection of ketamine / xylazine (100 mg / kg and 10 mg / kg). Before the incision, the planned incision area below the left rib near the stomach and the diaphragm were disinfected with povidone-iodine and 70% ethanol. The skin incision was less than 1 cm.

[0273] After aligning the peritoneum during dissection, the tail of the stomach was gently pulled out to straighten the esophagus for cell injection. Under a dissecting microscope, 10 μL of serum-free culture medium containing 1 × 10⁶ luciferase-labeled cells (KYSE-GFP-luc) was injected using an insulin syringe. 6 The cells were injected into the esophageal wall. Small edema at the injection site indicated successful cell injection. Tumor growth was confirmed by fluorescence and bioluminescence imaging 7 days post-surgery (Figure 55). Absorbable sutures were used to close the wound. During the procedure, the animal was kept warm on a heating pad until it fully regained its mobility. Body weight, hydration status, activity level, appetite, and behavior were monitored daily post-inoculation.

[0274] Fiber optic implantation and photoactivated EC therapy:

[0275] An implantable fiber optic device was assembled, equipped with a 660nm laser source, a glass conduit, and a small fiber optic cannula. A fiber optic core (0.22 NA, Thorlabs) was used to irradiate the esophageal lesion (Figure 6A). The location of the esophageal tumor was recorded to determine the insertion depth of the fiber optic cable. The therapeutic effect was assessed by monitoring tumor growth with different treatments. The esophageal tumor site was irradiated with light through the implanted fiber optic cable, and tumor growth was monitored using an IVIS system.

[0276] result

[0277] Synthesis and characterization of near-infrared BODIPY photocages with different structures

[0278] The synthesis of meso-methyl BODIPY cores has been reported in the literature (K. Long et al., One-photon red light-triggered disassembly of small-molecule nanoparticles for drug delivery. J. Nanobiotechnol. 19, 1-14 (2021); and T. Slanina et al., In search of the perfect photocage: structure–reactivity relationships in meso-methyl BODIPY photoremovable protecting groups. J. Am. Chem. Soc. 139, 15168-15175 (2017)). Using p-anisaldehyde as a starting material, NIR-responsive BODIPY ether 1 was synthesized via the Knoevenagel reaction, and then photocage 2 (NIR BODIPY-F2-OH, NBOF2-OH) was obtained by hydrolysis in NaOH solution. Replacing two fluorine molecules with methyl groups yielded compound 3, NIR BODIPY-Me2-OH, NBOMe2-OH, with an increased quantum yield in the photolysis reaction. Then, an iodination strategy was applied to the NIR BODIPY backbone to give compounds 4 (monoiodinated, NI1BOMe2-OH) and 5 (diiodinated, NI2BOMe2-OH). The newly synthesized BODIPY photocages (3-5) were purified by silica gel column chromatography and... 1 H-NMR and MS confirmed (not shown).

[0279] The UV-Vis spectra of different near-infrared BODIPYs revealed the structure-activity relationship of this series of photocages. After methyl substitution, the maximum absorption peak blue-shifted from 650 nm to 635 nm, corresponding to the methyl group being an electron-donating group that increased the electron density of the photocage molecule. In contrast, monoiodine and diiodine on NIR BODIPYs resulted in a red-shift in absorption, with peak values ​​at 640 nm and 645 nm, respectively (Figure 1).

[0280] BODIPY generates ROS under near-infrared light irradiation:

[0281] A response to singlet oxygen ( 1 The commercial indicator 1,3-diphenylisobenzofuran (DPBF) for O2 is used to monitor type II photodynamic effects under light irradiation (Figure 2). Generally, DPBF can be... 1 O2 degradation leads to reduced absorption at 410 nm. This is observed at 656 nm in the near-infrared region (1 mW / cm²). 2 At 0-15s, NI2BOMe2-OH was observed to show the highest [value / value]. 1 The O2 generation efficiency was even higher than that of methylene blue (MB), one of the clinically available photosensitizers. MB was used as a reference (0.52) to quantify (Φ( 1 The singlet oxygen quantum yields of O2 were calculated to be 0.00157 (compound 2), 0 (compound 3), 0.175 (compound 4), and 0.625 (compound 5), respectively.

[0282] It has been reported that methoxyphenyl plays an important role in enhancing type I PDT, namely, in addition to type II singlet oxygen, it also produces superoxide (O2). ·- (Y.-F. Xiao et al., Amplifying free radical generation of AIE photosensitizer with small singlet–triplet splitting for hypoxia-overcoming photodynamic therapy. ACS Appl. Mater. Interfaces 14, 5112-5121 (2022)). It is generally believed that type I PDT has superiority in tumor treatment due to reduced oxygen dependence. In order to study the effect of methoxyphenyl on the BODIPY backbone, dihydrorhodamine 123 (DHR123) and hydroxyphenyl fluorescein (HPF) were used as O2. ·- Specific probes for OH· can quantify the intensity of type I PDT under NIR light. It has been observed that NI₂BOMe₂-OH generates O₂. ·- It exhibits the highest efficiency in terms of OH·, while the yield of these substances in other BODIPY photocages is limited.

[0283] Iodization has been shown to be an effective strategy for enhancing the singlet-to-tritt transition of photosensitizers, thereby promoting their photodynamic therapy (PDT) effect (J. Atchison et al., Iodinated cyanine dyes: a new class of sensitisers for use in NIR activated photodynamic therapy (PDT). Chem. Commun. (Cambridge, UK) 53, 2009-2012 (2017)). To verify this, the fluorescence emission of different photocages was measured. The results showed that uniodinated BODIPY (2 and 3) exhibited stronger fluorescence emission, while iodization suppressed the fluorescence emission of compounds 4 and 5 (Figure 5). Using rhodamine 6G as a reference, the fluorescence quantum yield (Φ) was calculated. f The values ​​were 0.417 (compound 2), 0.336 (compound 3), 0.124 (compound 4), and 0.022 (compound 5).

[0284] In summary, the above results demonstrate that the diiodinated BODIPY photocage NI2BOMe2-OH (hereinafter referred to as NIBO) stands out among the BODIPY photocage series with high type I and type II PDT efficiencies (Figure 6). Density functional theory (DFT) calculations determined the HOMO and LUMO electron density distributions of the NIBO molecule. The higher LUMO electron density at the proposed cleavable site corresponds to previously reported BODIPY photocages, indicating that the hydroxyl site on NIBO is a cleavable site (Figure 7).

[0285] Synthesis of NIBO-RG108 prodrug for photoactivated combination therapy:

[0286] After confirming that the NIBO molecule is a near-infrared BODIPY photocage with enhanced photodynamic effects, its potential in photoactivated combination therapy (PCT) was validated by synthesizing a prodrug molecule designed to release ROS and load the drug under near-infrared light. Here, RG108 (N-phthalyl-L-tryptophan) was selected as the model drug loaded for conjugation with NIBO. RG108 is a DNA methyltransferase inhibitor (DNMTi) used to inhibit the activation of DNA methylation, thereby restoring the expression activity and function of tumor suppressor genes. However, as a key controller of epigenetic processes, the activity of DNA methyltransferases is also important in many healthy tissues, which is detrimental to systemic administration of DNMTi. Furthermore, some studies have shown a combined effect of RG108 and photodynamic therapy, but no studies have reported the combined photoactivated effect of PDT and RG108 release. RG108 was conjugated with NIBO via a simple and efficient esterification reaction. The product, NIBO-RG108 prodrug (NIRG), was purified by HPLC and then... 1 H-NMR characterization.

[0287] The photodynamic effects of the NIRG prodrug were first investigated using DPBF, DHR 123, and HPA probes. A slight reduction in ROS production was observed, primarily due to the consumption of some quantum energy during photolysis (Figure 8). The irradiated light (656 nm, 100 mW / cm²) was analyzed using HPLC. 2 The release of RG108 was detected by photo-activated drug delivery (0-10 minutes). Most NIRG prodrugs were observed to be converted into free RG108 within 10 minutes, demonstrating relatively high photoactivated drug release efficiency (Figures 9 and 10). It has been proposed that NIRG can generate ROS and RG108, thus producing a combined therapeutic effect in tumor cells (Figure 11), where ROS can promote the activation of the cell death marker caspase 3, and RG108 can increase GSDME expression. The aforementioned combined pharmacological effect was first verified by analyzing cell lysates after different treatments using MTT assays (Figure 12) and Western blotting (Figure 13). Furthermore, cells exhibited completely different morphologies after treatment with NIBO or NIRG plus light irradiation, indicating a combined effect of applying the PCT strategy to modulate the apoptosis pathway (PDT only) to the pyroptosis pathway (PDT + RG108) (Figure 14).

[0288] Synthesis and photolysis of NIBO-JQ and NIBO-Cb prodrugs:

[0289] Next, two additional prodrugs were synthesized to extend the above strategy using different bioactive molecules. JQ-1 (JQ) is a chemical drug that effectively inhibits the bromine domain and terminal extraterminal domain (BET) family of proteins such as BRD4, thereby inducing cell death and intratumoral immune activation, and has been validated in clinical trials. Here, photoactivated combination therapy of JQ-1 and NIBO was achieved. NIBO was conjugated with JQ-1 to generate the NIBO-JQ1 (NIJQ) prodrug using a method similar to that used in the preparation of NIRG. The trace product purified by HPLC was directly dissolved in acetonitrile / water (1:1) solution and subjected to 690 nm (100 mW / cm²) for photoactivation. 2 Irradiated with light for 15 min, followed by HPLC analysis of the solvent content. As shown in Figure 15, the HPLC elution curve indicates the release of photoactivated JQ from NIJQ. The UV-Vis spectrum of NIJQ shows two characteristic peaks for free JQ and NIBO, indicating their successful coupling (Figure 16).

[0290] Similarly, chlorambucil (Cb), another cytotoxic chemical, was caged by the NIBO photocage using the same method. HPLC and UV-Vis spectroscopy results both confirmed the successful production of NIBO-Cb (NICb) and its photolysis under near-infrared light (Figures 17 and 18). Based on the synthesis and characterization of NIRG, NIJQ, and NICb prodrugs, the feasibility of a photoactivation strategy utilizing NIBO photocages and carboxyl-containing drug molecules for chemical coupling and photolysis was verified.

[0291] Compritin A4 (CA4) is a clinically used angioplasty agent widely used in cancer treatment. The synthesis and NMR spectrum of IR820-CA4 (820CA), a NIR photoactivator prodrug for CA4, are shown in Figure 51.

[0292] NIRG and 820CA were observed to self-assemble into photoactivated nanoprodrugs via a simple and reliable process involving vigorous vortexing in aqueous solution (Fig. 19). The stable co-assembly capability of these prodrugs can be explained by complementary hydrophobicities, with NIRG exhibiting strong hydrophobicity and a tendency to form aggregates in water, while 820CA, being hydrophilic, acts as a stabilizer for the nanoscale aggregates. By monitoring the size and PDI of the resulting nanoparticles, an optimized 820CA / NIRG ratio of 1:1 (m / m) was observed (Fig. 20), with the nanoparticles exhibiting excellent stability over 5 days (Fig. 21). After co-assembly, the 820CA / NIRG NPD nanoparticles exhibited broad NIR absorption in the 650 nm to 850 nm range, indicating the composition of the two NIR photoactivated prodrugs (Fig. 22). Morphological changes were clearly visible by using TEM and comparing views of NP samples treated with / not treated with near-infrared light, which also corresponded to the size changes measured by DLS (Figs. 23 and 24).

[0293] Drug release was further validated using HPLC. Here, the 820CA / NIRG NPD can release two drug molecules under near-infrared light, which may indicate excellent phototargeted drug release behavior and combined antitumor effects.

[0294] It was observed that the release process of the two drugs was asynchronous, with the release efficiencies of RG108 and CA4 being approximately 60% and 40%, respectively (Figure 26).

[0295] ROS and CA4 have been reported to promote the activation of the cell death marker caspase 3, and RG108 can increase GSDME expression. The combined effects of photodynamic chemotherapy and elevated GSDME lead to a pyroptosis-dominated cell death pattern, thus NPD represents a new paradigm for precise pyroptosis therapy. The above pharmacological effects were validated by analyzing cell death patterns during treatment using fluorescence imaging, MTT assays, and Western blotting. It was observed that irradiation of NPD-treated cells with NIR light significantly increased ROS signaling and cell death (Figure 27).

[0296] Compared to dispersed single 820CA or NIRG, 820CA / NIRG NPD exhibited enhanced ROS generation and cytotoxicity, which was also verified by MTT assays in the human EC cell line KYSE-450 and the mouse cell line mEC25 (Figs. 28 and 29). To elucidate the pharmacological effects of PDT and drug release, Ctrl NP (IR820 / NIBO, without RG and CA) or NPD (820CA / NIRG nanoprodrug, releasing RG and CA) were compared. Cells exhibited drastically different morphologies after treatment; Ctrl NP induced apoptosis with significant cell shrinkage, while NPD altered the cell death pattern to pyroptosis, resulting in cell swelling and rupture (Fig. 30). Furthermore, free CA4 or NPD was observed to exhibit cell cycle arrest under near-infrared light, indicating the inhibitory effect of CA4 molecules on tubulin (Figs. 52 and 53). Caspase-3 (a cell death marker) increased after NPD light irradiation treatment, consistent with the above results (Fig. 31).

[0297] It has been reported that pyroptosis-mediated immunogenic cell death (ICD) can promote systemic anti-tumor immunity, thereby minimizing tumor proliferation and metastasis.

[0298] As an important marker of ICD, exposure to calreticulin CRT (“eat me” signal) and the release of DAMPs such as HMGB1, ATP, and LDH (“find me” signal) were evaluated. CLSM imaging showed that NPD under light irradiation increased CRT exposure and the release of HMGB1, ATP, and LDH in tumor cells (Figs. 32 and 33). Notably, NPD (releasing RG and CA under light) exhibited a greater ICD effect compared to Ctrl NP (PDT only), indicating that cell death patterns are important in the relevant process. Furthermore, Western blot analysis showed that NPD could increase the level of the active N-terminal cleavage fragment of Gasdermin E (GSDME-N), a marker of pyroptosis. To verify the immunogenicity of tumor cells after photoactivated prodrug treatment, the supernatant of the treated cancer cells was collected and incubated with primary bone marrow-derived dendritic cells (BMDCs) (Fig. 35). Cells treated with NPD and light showed the highest potential to induce BMDC maturation (labeled as CD80 and CD86 levels, Fig. 36), suggesting that pyroptosis-mediated cell death is beneficial for tumor immunotherapy.

[0299] To improve the precision and efficiency of prodrug photoactivation, tumor accumulation of free prodrug and nanoprodrug was compared in mice with subcutaneous tumors after intravenous injection. NPD accumulation in tumors remained at relatively high levels for 4–24 hours, while free prodrug was rapidly eliminated and showed no accumulation in tumors (Figure 54). Previous studies have found that caveolin mediates enhanced tumor uptake of anthocyanin-derived nanoparticles, such as the IR-783 nanoparticles studied previously and IR-820 in this paper.

[0300] Six-week-old C57BL / 6 mice were randomly divided into three groups (control group, Ctrl NP+hv group, and NPD+hv group, 5 mg / kg) to establish a mEC25 mouse subcutaneous tumor model. mEC25 is an EC cell line isolated from C57BL / 6 mice. As an syngeneic EC tumor, it possesses inherent immune escape characteristics. At the start of the experiment, 2 million mEC25 tumor cells were suspended in 100 μL PBS and subcutaneously injected into the flank of the mice. Subcutaneous tumor growth was observed seven days later. Here, the efficacy of nanoparticles inducing different cell death modes (Ctrl NP for apoptosis, NPD for pyroptosis) and their therapeutic effects on EC were compared. Four hours after intravenous injection of nanoparticles, the tumor was locally irradiated (660 nm, 100 mW / cm²). 2 (Figure 37). It was observed that NPD showed a greater anti-tumor effect as tumor volume decreased, with two out of four mice showing complete tumor elimination, while the apoptosis-induced control NP showed limited anti-tumor effect (Figures 38 and 39). Neither treatment showed significant side effects. Further investigation was conducted on systemic anti-tumor immunity after different treatments. ELISA serum analysis showed elevated levels of pro-inflammatory factors (e.g., interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α)), indicating that treatment induced an immune response (Figure 40).

[0301] In addition, flow cytometry was used to assess the immune response in peripheral immune organs, such as the spleen and tumor draining lymph nodes (tdLNs). Here, dendritic cells and T cells in these immune organs were the primary focus. It was observed that the proportion of mature dendritic cells (CD80+ / CD86+ in CD11c+ cells) increased in both the spleen and tdLNs after photoactivated nanodrug therapy, indicating the release of tumor antigens during treatment. Furthermore, dendritic cells (DCs) presented antigens to naive T cells and stimulated their proliferation and adaptive immune responses. To validate this, the CD8+ T cell population within the entire CD3+ T cell population was analyzed, and NPD in the light-irradiated group significantly increased this cytotoxic T cell population (Figures 41–44). Overall, photoactivated pyroptosis induced by nanodrugs triggered a stronger systemic tumor immune response compared to PDT-induced apoptosis.

[0302] Flexible optical fibers are the perfect tool for transmitting light to deep tissues. Fiber optic endoscopes are commonly used clinically for the non-invasive diagnosis of digestive tract diseases such as esophageal diseases and gastric ulcers.

[0303] The use of fiber optic systems can precisely guide the diagnosis and treatment of esophageal cancer patients, offering high visibility. Here, using a fiber optic system to precisely control prodrug activation in esophageal tumor areas provides a clinically relevant example for the application of this therapy.

[0304] The fiber optic cable was set to approximately 20 mm in length, allowing for pre-determining of tumor location via IVIS imaging. Due to its slender shape, using a plastic gavage needle to guide the cable into the esophagus minimizes tissue damage or accidental fiber injury. Four hours after intravenous injection of different formulations (dose: 5 mg / kg), photoirradiation (100 mW / cm²) was performed. 2 (10 min) (Figure 45). Mice were divided into 5 groups and received different treatments, including: A. saline; B: free RG+CA; C: Ctrl NP+hv; D: NPD in the dark; E: NPD+hv. During 15 days of IVIS monitoring, tumor growth was eliminated in all mice in the NPD+phototherapy group, while the other groups showed significant tumor growth signals. By quantifying the luminescence intensity, it was found that saline, free drug, and nanoparticles without light did not inhibit tumors, while control nanoparticles without drug molecules showed limited efficacy (Figures 46, 47, and 48).

[0305] Immunofluorescence staining of tumor tissue showed a significant decrease in CD31 and an increase in TUNEL, indicating that near-infrared nanoparticles can inhibit the vascular system in tumors and lead to tumor cell death (Figure 49). These pathological features suggest a combined antitumor effect of the treatment. At the end of the experiment, no significant necrosis was observed in major organs other than the tumor (Figure 56), indicating that intravenous injection of nanoparticles into esophageal tumors with fiber optic light irradiation resulted in minimal systemic toxicity.

[0306] in conclusion:

[0307] The NIR-absorbing BODIPY photocage NIBO was developed through rational chemical modification of the traditional BODIPY backbone. It exhibits type I / II PDT activity and load release capability under NIR light. Based on these intriguing properties, a novel strategy called "photoactivated combination therapy" has been developed for cancer treatment. By combining RG108, CA4, and photodynamic effects, the cell death mode shifts from apoptosis to pyroptosis, significantly enhancing immunogenic cell death. Based on the precise activation mechanism of the prodrug, this invention can selectively initiate pyroptosis at the tumor lesion site, while the nanoprodrug remains in an inactive form in tissues without light irradiation. It represents a new paradigm for using photoresponsive prodrugs to trigger precise pyroptosis, thereby minimizing side effects and improving safety. Furthermore, this invention has successfully developed an orthotopic esophageal tumor model, in which optical fibers are implanted for light irradiation during treatment. For fiber implantation, an implantable optical fiber device with a near-infrared light source was assembled. With the successful implantation of the optical fiber, the limitation of poor light penetration was overcome, and excellent anti-tumor effects were achieved; all tumor-bearing mice treated with a single dose recovered. Overall, this invention provides an innovative method for precision tumor immunotherapy using photoresponsive prodrugs, and has great potential for clinical translation.

[0308] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A photocage compound having the structure of Formula I: in, X is selected from hydrogen or halogen, and at least one X group is not hydrogen; R1-R5 are each independently selected from hydrogen, C1-C6. 10 An amino group substituted with alkoxy or dialkyl groups, and at least one of the R1-R5 substituents is not hydrogen; R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy or dialkyl substituted amino groups, and R6-R 10 At least one of the substituents is not hydrogen; R 11 R 13 Each is independently selected from C1-C 10 alkyl; R 12 The R” is a cleavable group selected from –OH, –SH, –NH2, or –NHR”; wherein R” is C1-C 10 alkyl; R 14 R 15 Each is independently selected from halogens, C1-C 10 Alkyl or C1-C 10 alkoxy groups; and R 16 R 17 Each is independently selected from hydrogen, C1-C 10 alkyl.

2. The photocage compound according to claim 1, characterized in that: Each X represents iodine.

3. The photocage compound according to claim 1, characterized in that: R3 and / or R8 are alkoxy- or dialkyl-substituted amino groups, and R1-R2, R4-R5, R6-R7, and R9-R 10 It is hydrogen.

4. The photocage compound according to claim 1, characterized in that: R 14 and R 15 It is a methyl group.

5. The photocage compound according to claim 1, characterized in that: R 11 and R 13 It is a methyl group.

6. The photocage compound according to claim 1, characterized in that: The cleavable group is selected from –OH, –SH, –NH2, or –NHR”; where R” is C1-C 10 alkyl.

7. The photocage compound according to any one of claims 1-6, characterized in that, The photocage compound has the following structure:

8. A photocage prodrug compound having the structure of Formula II: in, D represents a cleavable drug structural unit containing a photocleavable linker; Each X is independently selected from halogens; R1-R5 are each independently selected from hydrogen, C1-C6. 10 An amino group substituted with alkoxy or dialkyl groups, and at least one of the R1-R5 substituents is not hydrogen; R6-R 10 Each is independently selected from hydrogen, C1-C 10 Alkoxy or dialkyl substituted amino groups, and R6-R 10 At least one of the substituents is not hydrogen; R 11 R 13 Each is independently selected from C1-C 10 alkyl; R 14 R 15 Each is independently selected from halogens, C1-C 10 Alkyl or C1-C 10 alkoxy groups; and R 16 R 17 Each is independently selected from hydrogen, C1-C 10 alkyl.

9. The photocage prodrug compound according to claim 8, characterized in that: Each X represents iodine.

10. The photocage prodrug compound according to claim 8, characterized in that: R3 and / or R8 are alkoxy- or dialkyl-substituted amino groups, and R1-R2, R4-R5, R6-R7, and R9-R 10 It is hydrogen.

11. The photocage prodrug compound according to claim 8, characterized in that: R 14 and R 15 It is a methyl group.

12. The photocage prodrug compound according to claim 8, characterized in that: R 11 and R 13 It is a methyl group.

13. The photocage prodrug compound according to claim 8, characterized in that: The photolytically cleavable portion includes the ester group (-OC(O)-).

14. The photocage prodrug compound according to any one of claims 8-13, characterized in that: The cleavable drug portion D has one of the following structures:

15. The photocage prodrug compound according to any one of claims 8-13, characterized in that: The photocage prodrug compound described herein has one of the following structures:

16. A pharmaceutical composition, characterized in that: Include: The photocage prodrug compound according to any one of claims 8-15; and At least one pharmaceutically acceptable carrier.

17. The pharmaceutical composition according to claim 16, characterized in that: The at least one pharmaceutically acceptable carrier is selected from water, ethanol, polyethylene glycol, propylene glycol, chitosan polymers and chitosan derivatives, methylcellulose, and oil.

18. The pharmaceutical composition according to claim 16, characterized in that: The pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

19. The pharmaceutical composition according to any one of claims 16-18, characterized in that: The pharmaceutical composition further comprises one or more therapeutic agents, preventive agents, or diagnostic agents.

20. The pharmaceutical composition according to claim 19, characterized in that: The one or more therapeutic agents, preventive agents or diagnostic agents are contained within self-assembled nanocarriers (nanoparticles).

21. The pharmaceutical composition according to claim 20, characterized in that: The therapeutic, preventive, or diagnostic agents include bronchodilators, corticosteroids, methylxanthine, phosphodiesterase-4 inhibitors, anti-angiogenic agents, antibiotics, antioxidants, antiviral agents, antifungal agents, anti-inflammatory agents, immunosuppressants, anti-allergic agents, photosensitizers, and combinations thereof.

22. The pharmaceutical composition according to claim 21, characterized in that: The anti-angiogenic agents include colchicine derivatives, compressorides, and TNP-470.

23. The pharmaceutical composition according to claim 21, characterized in that: The photosensitizer includes cyanine dye molecules.

24. The pharmaceutical composition according to claim 20, characterized in that: The therapeutic agent includes the following compounds:

25. The pharmaceutical composition according to claim 24, characterized in that: The mass ratio of the therapeutic agent to the photocure prodrug compound is (1-4):(1-2).

26. A method for performing photoactivated combination therapy (PCT), characterized in that: Includes the following steps: (i) administering to a subject in need the pharmaceutical composition comprising any one of claims 16-24; and (ii) Irradiate the photocage prodrug compound of the pharmaceutical composition with a sufficient dose of light (e.g., near-infrared light) to generate reactive oxygen species (ROS) and induce photolysis and release of at least some of the cleavable drug fractions.

27. The method according to claim 26, characterized in that: The light is near-infrared (NIR) light and optionally has a wavelength range from approximately 650 nm to 900 nm.

28. The method according to any one of claims 26-27, characterized in that: The light has a power of approximately 1mW / cm 2 Up to 500mW / cm 2 1mW / cm 2 Up to 250mW / cm 2 1mW / cm 2 Up to 100mW / cm 2 1mW / cm 2 Up to 50mW / cm 2 1mW / cm 2 Up to 500mW / cm 2 1mW / cm 2 Up to 250mW / cm 2 1mW / cm 2 Up to 100mW / cm 2 1mW / cm 2 Up to 50mW / cm 2 1mW / cm 2 Up to 25mW / cm 2 or 1mW / cm 2 Up to 10mW / cm 2 Output intensity within the range of; or approximately 1 mW / cm 2 10mW / cm 2 20mW / cm 2 30mW / cm 2 40mW / cm 2 50mW / cm 2 60mW / cm 2 70mW / cm 2 80mW / cm 2 90mW / cm 2 Or 100mW / cm 2 .

29. The method according to any one of claims 26-28, characterized in that: The duration of the light irradiation is approximately 0.1 seconds to 15 seconds, 0.01 seconds to 15 minutes, 0.01 seconds to 10 minutes, 0.01 seconds to 5 minutes, 0.01 seconds to 2.5 minutes, or 0.01 seconds to 1 minute; or at least approximately 0.01 seconds, 10 seconds, 15 seconds, 1 minute, 2.5 minutes, 5 minutes, 10 minutes, or 15 minutes.

30. The method according to any one of claims 26-29, characterized in that: The subjects had cancer (e.g., esophageal squamous cell carcinoma, colon cancer, or melanoma).

31. The method according to any one of claims 26-30, characterized in that: The pharmaceutical composition is administered to the tumor of the subject.

32. The method according to any one of claims 26-31, characterized in that: The photocage prodrug compound of the pharmaceutical composition is present after steps (i) and (ii) to effectively treat cancer or tumor, inhibit cancer or tumor, and / or reduce the concentration of cancer or tumor.

33. The method according to any one of claims 26-32, characterized in that: The pharmaceutical composition is administered to the subject via intranasal administration, oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, or a combination thereof.

34. The method according to any one of claims 26-33, characterized in that: The method also includes co-administering one or more therapeutic agents, preventative agents, or diagnostic agents to the subjects.

35. Use of the photocage prodrug compound of any one of claims 8-15 or the pharmaceutical composition of any one of claims 16-25 in the preparation of a medicament for photoactivated combination therapy.

36. Use of the photocage prodrug compound of any one of claims 8-15 or the pharmaceutical composition of any one of claims 16-25 in the preparation of a medicament for treating tumors.

37. The use according to claim 36, characterized in that: The treatment includes photoactivation combined therapy.

38. The use according to claim 35 or 37, characterized in that: The light is near-infrared and optionally has a wavelength range between about 650 and 900 nm.

39. The use according to claim 38, characterized in that: The light has a power of approximately 1mW / cm 2 Up to 500mW / cm 2 The output intensity is within the range between [a certain value].

40. The use according to claim 38, characterized in that: The illumination time of the light ranges from approximately 0.01 seconds to 15 minutes.

41. The use according to claim 36, characterized in that: The tumors include esophageal squamous cell carcinoma, colon cancer, or melanoma.

42. The use according to claim 36, characterized in that: The routes of administration of the drug include intranasal administration, oral administration, intramuscular administration, intravenous administration, intraperitoneal administration, subcutaneous administration, or combinations thereof.

43. The use according to claim 36, characterized in that: The drug also includes one or more therapeutic agents, preventive agents, or diagnostic agents.

44. A treatment system, characterized in that: include: The photocage prodrug compound according to any one of claims 8-15 or the pharmaceutical composition according to any one of claims 16-25; and (i) A non-implantable laser therapy device; said non-implantable laser therapy device includes a power supply, a laser generator, and a light guide assembly; or (ii) An implantable fiber optic therapy device; the implantable fiber optic therapy device includes a laser source, a catheter, and a fiber optic assembly.

45. The treatment system according to claim 44, characterized in that: The treatment system also includes an imaging system.